Cargando…

A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19

Background: A large number of people contracted moderate-type COVID-19 around the world. However, to our knowledge no studies have covered the clinical course of patients with moderate-type COVID-19. This study describes the clinical course of moderate-type patients with COVID-19 from Wuhan City and...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xiaohua, Lv, Xin, Song, Cheng, Jiang, Mao, He, Ronglin, Han, Yuanyuan, Li, Mengyu, Zhang, Yan, Jiang, Yupeng, Meng, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112071/
https://www.ncbi.nlm.nih.gov/pubmed/33987158
http://dx.doi.org/10.3389/fpubh.2021.593109
_version_ 1783690624041484288
author Liao, Xiaohua
Lv, Xin
Song, Cheng
Jiang, Mao
He, Ronglin
Han, Yuanyuan
Li, Mengyu
Zhang, Yan
Jiang, Yupeng
Meng, Jie
author_facet Liao, Xiaohua
Lv, Xin
Song, Cheng
Jiang, Mao
He, Ronglin
Han, Yuanyuan
Li, Mengyu
Zhang, Yan
Jiang, Yupeng
Meng, Jie
author_sort Liao, Xiaohua
collection PubMed
description Background: A large number of people contracted moderate-type COVID-19 around the world. However, to our knowledge no studies have covered the clinical course of patients with moderate-type COVID-19. This study describes the clinical course of moderate-type patients with COVID-19 from Wuhan City and Yiyang City, and explores factors relevant to the length of hospitalization and symptoms relief. Methods: The study analyzed the clinical course of 107 moderate-type patients with COVID-19 from the outbreak area (Wuhan) and the imported area (Yiyang), and used automatic linear modeling and multivariate linear regression analysis to explore the factors relevant to the length of hospitalization and symptoms relief. Furthermore, we created a scoring system to value the length of hospitalization and symptoms relief. Results: Lymphopenia, elevated C-reactive protein, increased LDH, bilateral lung GGO (ground glass opacity), and lung consolidation were more likely to appear in ordinary inpatients with moderate-type COVID-19 from Wuhan (P < 0.05), compared to infected medical staff from Wuhan and ordinary inpatients with moderate-type COVID-19 from Yiyang. Meanwhile, the length of hospitalization and symptoms relief was longer in ordinary patients with moderate-type COVID-19 from Wuhan (P < 0.05). Onset of symptoms to admission, ESR, leucocytes count, and bilateral lung GGO were linearly related to the length of hospitalization (P < 0.05); onset of symptoms to admission, leucocytes count, bilateral lung GGO, and lung consolidation were linearly related to the length of symptoms relief (P < 0.05). By using the scoring system, we found that the time of hospitalization and symptoms relief lengthened as the scores increased. Conclusions: This study described the clinical course of patients with moderate-type COVID-19, and found that ordinary patients with moderate-type COVID-19 in outbreak areas were more serious and needed stronger treatment and longer treatment time. Onset of symptoms to admission, ESR, leucocytes count, and bilateral lung GGO can be effective predictors of the length of hospitalization. And onset of symptoms to admission, leucocytes count, bilateral lung GGO, and lung consolidation can be effective predictors of the amount of time until symptoms relief. Most importantly, we have created a scoring system, which could contribute to the diagnosis and treatment of COVID-19.
format Online
Article
Text
id pubmed-8112071
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81120712021-05-12 A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19 Liao, Xiaohua Lv, Xin Song, Cheng Jiang, Mao He, Ronglin Han, Yuanyuan Li, Mengyu Zhang, Yan Jiang, Yupeng Meng, Jie Front Public Health Public Health Background: A large number of people contracted moderate-type COVID-19 around the world. However, to our knowledge no studies have covered the clinical course of patients with moderate-type COVID-19. This study describes the clinical course of moderate-type patients with COVID-19 from Wuhan City and Yiyang City, and explores factors relevant to the length of hospitalization and symptoms relief. Methods: The study analyzed the clinical course of 107 moderate-type patients with COVID-19 from the outbreak area (Wuhan) and the imported area (Yiyang), and used automatic linear modeling and multivariate linear regression analysis to explore the factors relevant to the length of hospitalization and symptoms relief. Furthermore, we created a scoring system to value the length of hospitalization and symptoms relief. Results: Lymphopenia, elevated C-reactive protein, increased LDH, bilateral lung GGO (ground glass opacity), and lung consolidation were more likely to appear in ordinary inpatients with moderate-type COVID-19 from Wuhan (P < 0.05), compared to infected medical staff from Wuhan and ordinary inpatients with moderate-type COVID-19 from Yiyang. Meanwhile, the length of hospitalization and symptoms relief was longer in ordinary patients with moderate-type COVID-19 from Wuhan (P < 0.05). Onset of symptoms to admission, ESR, leucocytes count, and bilateral lung GGO were linearly related to the length of hospitalization (P < 0.05); onset of symptoms to admission, leucocytes count, bilateral lung GGO, and lung consolidation were linearly related to the length of symptoms relief (P < 0.05). By using the scoring system, we found that the time of hospitalization and symptoms relief lengthened as the scores increased. Conclusions: This study described the clinical course of patients with moderate-type COVID-19, and found that ordinary patients with moderate-type COVID-19 in outbreak areas were more serious and needed stronger treatment and longer treatment time. Onset of symptoms to admission, ESR, leucocytes count, and bilateral lung GGO can be effective predictors of the length of hospitalization. And onset of symptoms to admission, leucocytes count, bilateral lung GGO, and lung consolidation can be effective predictors of the amount of time until symptoms relief. Most importantly, we have created a scoring system, which could contribute to the diagnosis and treatment of COVID-19. Frontiers Media S.A. 2021-04-26 /pmc/articles/PMC8112071/ /pubmed/33987158 http://dx.doi.org/10.3389/fpubh.2021.593109 Text en Copyright © 2021 Liao, Lv, Song, Jiang, He, Han, Li, Zhang, Jiang and Meng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Liao, Xiaohua
Lv, Xin
Song, Cheng
Jiang, Mao
He, Ronglin
Han, Yuanyuan
Li, Mengyu
Zhang, Yan
Jiang, Yupeng
Meng, Jie
A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19
title A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19
title_full A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19
title_fullStr A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19
title_full_unstemmed A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19
title_short A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19
title_sort retrospective cohort study on the clinical course of patients with moderate-type covid-19
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112071/
https://www.ncbi.nlm.nih.gov/pubmed/33987158
http://dx.doi.org/10.3389/fpubh.2021.593109
work_keys_str_mv AT liaoxiaohua aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT lvxin aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT songcheng aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT jiangmao aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT heronglin aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT hanyuanyuan aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT limengyu aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT zhangyan aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT jiangyupeng aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT mengjie aretrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT liaoxiaohua retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT lvxin retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT songcheng retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT jiangmao retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT heronglin retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT hanyuanyuan retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT limengyu retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT zhangyan retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT jiangyupeng retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19
AT mengjie retrospectivecohortstudyontheclinicalcourseofpatientswithmoderatetypecovid19